Aquestive Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-15
- Employees
- 135
- Market Cap
- $421.6M
- Website
- http://www.aquestive.com
- Introduction
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Aquestive Therapeutics stock poised for potential breakthrough
Aquestive Therapeutics advances Anaphylm, a sublingual epinephrine film for anaphylaxis treatment, with promising clinical data and a planned NDA submission in Q1 2025. The product's unique administration and stability could expand the epinephrine market, with analysts projecting peak sales of $300-400 million. However, regulatory risks and market competition pose challenges.
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
Aquestive Therapeutics to hold virtual investor day on Sept 27 to discuss pipeline updates, including Anaphylm™ Sublingual Film and AQST-108 Topical Gel, both from the Adrenaverse™ epinephrine prodrug platform. Event features presentations by Aquestive management and key opinion leader J. David Farrar, PhD.
Epinephrine Nasal Spray to Treat Anaphylaxis is Now Available
neffy®, a needle-free epinephrine nasal spray for anaphylaxis, is now available by prescription. Approved by the FDA, it offers an alternative to auto-injectors, with similar efficacy and mild side effects. Studies show high patient preference for nasal sprays over injections. neffy is compact, easy to use, and accessible through various pricing programs.
© Copyright 2025. All Rights Reserved by MedPath